Aurobindo Pharma strengthens oncology portfolio with UK approval

step-down subsidiary, CuraTeQ Biologics s.r.o., has secured marketing authorisation from the UK’s MHRA for Dazublys, a trastuzumab biosimilar used in treating HER2-positive breast and gastric cancers, marking its fourth biosimilar approval in the UK after Bevqolva (Dec 2024), Zefylt (May 2025), and Dyrupeg (June 2025). Notably, Dazublys, Zefylt, and Dyrupeg have also gained European Commission approval, expanding CuraTeQ’s footprint in the EU oncology market. This regulatory milestone comes alongside early-stage discussions for a potential acquisition of Zentiva, a Europe-based player, which Aurobindo’s CFO highlighted as strategically aligned though still at a nascent stage. With $140 million in assets and 75% of revenues sourced from the US and European markets, Aurobindo continues to deepen its global positioning in biosimilars, while maintaining a disciplined acquisition approach by targeting deals at single-digit multiples. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.